Evidence map›Paper›PMID 37206623›Full record

ArticleOpen forum infectious diseases2023

Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections.

Daniel A Sweeney, Bonifride Tuyishimire, Neera Ahuja, John H Beigel, Tatiana Beresnev, Valeria D Cantos, Jose G Castro, Stuart H Cohen, Kaitlyn Cross, Lori E Dodd and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead.ACS pharmacology & translational science · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Daniel A SweeneyDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID https://orcid.org/0000-0002-5398-3528
Bonifride TuyishimireThe Emmes Company, LLC, Rockville, MD, USA.
Neera AhujaDepartment of Medicine, Stanford University, Palo Alto, CA, USA.
John H BeigelNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Tatiana BeresnevNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Valeria D CantosDepartment of Medicine, Emory University, Atlanta, GA, USA.
Jose G CastroDepartment of Medicine, University of Miami, Miami, FL, USA.
Stuart H CohenDepartment of Internal Medicine, University of California Davis, Sacramento, CA, USA.
Kaitlyn CrossThe Emmes Company, LLC, Rockville, MD, USA.
Lori E DoddNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Nathan ErdmannDepartment of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA.
Monica FungDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Varduhi GhazaryanNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Sarah L GeorgeDepartment of Medicine, Saint Louis University and St. Louis VA Medical Center, Saint Louis, MO, USA.
Kevin A GrimesDepartment of Medicine, Houston Methodist, Houston, TX, USA.
Noreen A HynesDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kathleen G JulianDepartment of Medicine, Pennsylvania State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Sheetal KandiahDepartment of Medicine, Emory University, Atlanta, GA, USA.
Hannah Jang KimCommunity Health Systems Department, University of California San Francisco, San Francisco, CA, USA.
Corri B LevineDepartment of Internal Medicine Galveston, University of Texas Medical Branch, TX, USA.
David A LindholmDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
David C LyeNational Centre for Infectious Diseases, Singapore, Singapore.
Ryan C MavesDepartments of Internal Medicine and Anesthesiology, Wake Forest University, Winston-Salem, NC, USA.
Myoung-Don OhDepartment of Internal Medicine, Seoul National University Hospital College of Medicine, Seoul, Korea.
Catharine PaulesDepartment of Medicine, Pennsylvania State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Rekha R RapakaDepartment of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Willam R ShortDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kay M TomashekNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Cameron R WolfeDepartment of Medicine, Duke University, Durham, NC, USA.
Andre C KalilDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Funding

Vaccine and Treatment Evaluation Unit at Saint Louis University - DMID 20-0034UM1AI148685 · NIAID · SAINT LOUIS UNIVERSITY · PI Daniel F. Hoft · 2020 to 2026
$34.6M
Human Cellular Immune Programming Against Invasive SalmonellaK08AI143923 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI RAPAKA, REKHA R · 2019 to 2023
$798k
Determine if a candidate dengue vaccine in advanced trials induces antigen-specific cellular immunity that mimics immunity after multiple infections and controls antibody-enhanced viral replicationI01BX003714 · VA · ST. LOUIS VA MEDICAL CENTER · PI GEORGE, SARAH · 2017 to 2020
–
BLRD VA I01 BX003714NIAID NIH HHS K08 AI143923NIAID NIH HHS UM1 AI148685
6 · The paper itself

Abstract

We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.

Indexed as

baricitinibCOVID-19secondary infections

Identifiers

PMID37206623
PMCPMC10191442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.